Linker Payload Services -Abzena

Are you looking to simplify & secure your supply chain?

Abzena are not just reacting to potential tariff changes - we are striving to proactively reshape our supply chain strategy for biologics to help customers thrive in a complex global biopharma market.

Watch Video Contact Us

In an ever-shifting global trade environment for biologics, potential tariffs need not be a threat; they are an opportunity to innovate and strengthen operational resilience for the benefit of our customers. We are committed to offering a fully integrated US and UK network. This brings together mAb production, conjugation, sterile filling, lyophilization, and packaging – helping us stay ahead shifting geopolitical and supply-chain dynamics that could knock critical programs off-track.

Staying true to our mission and values, and by concentrating on cost management, cultivating strategic partnerships, prioritizing robust quality compliance, proactively managing risk, and embracing holistic supply chain transformation, Abzena are leading the way in turning tariff-related complexities into competitive advantages for your business to succeed.

We are dedicated to ensuring that agility, innovation, and performance remain front and center—so you can focus on delivering transformative therapies to patients, confident that your supply chain is optimized, future-focused, and ready to adapt to whatever could lie ahead.

Watch our video below to learn about how we can help de-risk your program.

The drug development supply chain is a web of interconnected processes that MUST work seamlessly for drugs to reliably reach patients on time. In today’s fast-paced climate, drug developers are faced with new and complex challenges from supply-demand imbalance to an evolving regulatory landscape and uncertainties about new legislation.

In the face of growing complexity, and with the constant pressure to innovate, how can drug developers navigate these challenges effectively? When any disruption in the supply chain can seriously damage prospects for success. How do you minimize risk, while still ensuring a consistent, high-quality product?

At Abzena, we understand that you can’t afford a weak link in your supply chain. With over two decades of experience advancing biologics, bioconjugates including ADCs, AOCs, RDCs, and fully integrated, end-to-end CDMO services that span from early discovery through commercial supply, we have the answers, experience and stability you need.

With a flexible and agile approach, we build our strategy around your project-specific goals, timeline, and budget. Risk-mitigation is always top of mind. Our team of expert scientists in the US and UK are ready to start solving your complex challenges right now, so you can reach your next milestone faster. Ready to simplify and secure your supply chain?

Contact Us

Reshaping Our Supply Chain Strategy

Growing R&D activities, personalized medicines, large-scale production of biologics, and access to new technologies are driving substantial growth and interest in biopharmaceuticals. In a recent article with ‘Drug Development & Delivery’, Dr. Campbell Bunce, Chief Scientific Officer of Abzena discussed how we are reshaping our supply chain strategy to help customers thrive in a complex, ever-growing global biologics market.

“In the current geopolitical landscape, and among recent discussions about tariffs on pharmaceutical products and the BioSecure Act, our fully integrated, U.S. based manufacturing model offers a strategic advantage, often delivering a 25% price edge over many international competitors. By leveraging domestic partners for sterile filling, lyophilization, and packaging, we effectively manage the entire supply chain from monoclonal antibody (mAb) production to final drug product within the United States. This approach helps us minimize the unknown risks posed by global trade shifts for our customers.”

Dr. Campbell Bunce, Chief Scientific Officer of Abzena

Our Supply Approach: Driven By 5 Key Considerations

To assist our US-based customers navigate any potential tariff challenges, there are five key considerations that drive our approach and help move your medicine forward. From monoclonal antibody (mAbs) production to final drug product fill-finish and packaging, our ‘nationalized’ US supply chain strategy reduces complexity and maintains resilience.

1. Navigating Potential Cost Implications

Direct Cost Management

Challenge: Tariffs could directly drive up the cost of imported raw materials and components.
Solution: By integrating mAb production, conjugation, and drug product manufacturing under one roof (or in collaboration with our domestic partners), Abzena avoids potential cost escalations associated with offshore suppliers in tariff-prone regions. This structure reinforces our 25% price advantage and keeps us focused on proactively managing program costs.

Controlling Indirect Expenses

Challenge: Beyond headline duties, tariffs could raise customs brokerage fees, administrative costs, and logistics complexities.
Solution: By centralizing operations within the U.S., Abzena helps minimize these possible indirect expenses and maintains a predictable, streamlined cost structure. This domestic-first model ensures steady operational agility and supports precise budgeting across all stages of the supply chain.

2. Enhancing Supplier Relationships & Diversification

Strategic Supplier Partnerships

Challenge: Potential tariffs highlight the risks of over-reliance on specific regions for vital inputs.
Solution: Abzena cultivate deeply integrated, long-term partnerships rather than mere transactional relationships. By engaging suppliers early and leveraging digital connectivity, we build a diverse network designed to respond quickly to changes in trade policies and geopolitical circumstances.

Integrated Manufacturing Advantage

Challenge: There are some CDMOs may only handle conjugation by importing mAbs.
Solution: Our holistic model covers everything from mAb production to sterile fill-finish and packaging. Eliminating reliance on multiple external suppliers could help reduce exposure to multiple tariff layers, further lowering risk while streamlining processes and costs. This positions us as a truly strategic partner to our customers, particularly in times of trade uncertainty.

3. Strengthening Customs & Compliance

Staying Ahead of Regulatory Shifts

Challenge: Tariffs could coincide with regulatory updates that complicate cross-border trade.
Solution: Thanks to our U.S.-based infrastructure and robust compliance frameworks, Abzena can manage potential changes in documentation and country-of-origin rules without jeopardizing timelines. By focusing on a domestically anchored supply chain, we minimize the hurdles posed by shifting international regulations.

Streamlined Digital Processes

Challenge: Tariffs could mean additional stages and documentation requirements.
Solution: We incorporate digital tools and real-time analytics to efficiently manage customs operations, documentation, and distribution. This integrated approach optimizes our workflows, ensuring prompt clearance at every stage of the process.

4. Proactive Risk Management & Contingency Planning

Strategic “What-If” Scenarios

Challenge: The tariff landscape is inherently unpredictable.
Solution: We continually work to model various scenarios to better gauge impacts on inventory, lead times, and costs. These simulations inform decisions about how to allocate resources, where to place safety stock, and how to plan manufacturing activities—even if market conditions shift rapidly.

Resilient Inventory Strategies

Challenge: External pressure on inventories could lead to disruption and increased lead times.
Solution: Potential tariff-induced disruptions could be mitigated by strategic inventory allocation. Abzena’s commitment to nationalizing our entire supply chain—from mAb production through final drug product manufacturing—facilitates efficient, forward-looking inventory management. This ensures production continues smoothly, even if external factors become volatile.

5. Driving a Holistic Supply Chain Transformation

Optimizing the Entire Value Chain

Challenge: Tariffs could be a catalyst for rethinking and optimizing the entire supply chain structure.
Solution: Abzena’s domestically focused model—encompassing everything from mAb development to sterile filling, lyo, and packaging—could reduce tariff exposure, improve timeline predictability, and preserve our competitive pricing advantage. This comprehensive approach stands in stark contrast to more fragmented models reliant on outsourced components from countries vulnerable to tariffs.

Embracing Synergistic Partnerships

Challenge: Tariffs will create logistical challenges that without collaboration will not be able to pivot and be flexible enough to move forward fast enough.
Solution: We collaborate closely with logistics providers, technology vendors, and strategic suppliers to create a “nationalized” network that can pivot swiftly. This synergy not only addresses possible tariff challenges but also drives the kind of innovation that expedites high-quality therapies to market—ultimately benefiting patients.

Abzena & Argonaut Partnership

Abzena and Argonaut have a strategic partnership to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations. Removing the white space in drug development, this partnership delivers a streamlined approach for customers looking to rapidly progress therapies into the clinic, or onward into later-stage commercial manufacturing.

From early discovery services such as stable cell live development, through clinical and commercial manufacturing of drug substance and drug product. Our tight integration of activities facilitates more informed and rapid decision-making, efficient technology transfer, and a reduction in supply chain complexity.

About Abzena & Argonaut Partnership

Ready to simplify and secure your supply chain? Contact Abzena today.

From concept to commercialization, Abzena’s end-to-end biologics and bioconjugates services model delivers reduced risk, fewer hand-offs, transparent communication, and faster decision-making. These are the competitive advantages that we see matter for our customers, when markets are volatile and uncertainty over potential tariffs exists.

Related Insights + News

How the Tariffs Could Impact Your Drug Development Supply Chain: Top 5 Things To Be Aware Of

Learn More

24/7 Biopharma.com – CDMO & Supplier Partnerships: How are relationships evolving to foster agility and innovation?

Learn More

The Pharma Letter: The importance of onshoring and better control of the drug supply chain

Learn More

Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure

Learn More

Abzena & Argonaut Partner to Offer Accelerated End-to-End Drug Development Support

Learn More

Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy

Learn More